Kinfo
Immunic, Inc. logo

Immunic, Inc.

IMUXNASDAQHealthcare·US · USD
$7.36
-0.16 (-2.13%)
Prices as of November 16, 2026 · live

Price

Key statistics

Valuation
Market cap102.61M USD
Enterprise value-51.92M USD
Trailing P/E-1.18
Forward P/E-3.17
PEG ratio0.02
Price / sales0.00
Price / book2.45
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-66.80%
Return on equity-138.17%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-117.73M USD
Net income-111.57M USD
Diluted EPS-$3.83
Rev. growth (YoY)0.00%
Balance sheet
Total cash155.10M USD
Total debt567.00K USD
Debt / equity0.44
Current ratio5.05
Book value / share-$0.55
Cash flow (TTM)
Operating cash flow-87.72M USD
Levered free cash flow-51.41M USD
Shares & price
Shares outstanding13.64M
Float12.01M
Held by institutions76.15%
Beta1.48
50-day MA$8.70
200-day MA$11.56
52-week high$17.43
52-week low$5.06
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-13-0.95-0.99−4.21%2026-08-11-1.16-0.80+31.03%2026-07-291.191.35+13.45%2026-05-13-0.96-1.08−12.50%2026-02-26-1.11-0.70+36.94%
About Immunic, Inc.

Immunic, Inc. is a biotechnology company focused on developing selective oral therapies for chronic inflammatory, autoimmune, and neurologic diseases. Its current pipeline centers on small-molecule drug candidates designed to modulate immune activity and improve treatment options for conditions such as multiple sclerosis and ulcerative colitis. The company’s lead program, IMU-838, is being studied in late-stage and mid-stage clinical development, while IMU-856 is being advanced for gastrointestinal disorders linked to intestinal barrier dysfunction. Immunic also maintains earlier-stage research programs in immune-mediated diseases. With operations in the United States and Germany, Immunic, Inc. plays a role in the clinical-stage biopharmaceutical market by advancing oral, mechanism-based therapies aimed at complex inflammatory conditions.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Erik Lundgren
Employees
100
Headquarters
New York, NY, United States

Frequently asked questions about Immunic, Inc.